• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Innate Pharma S.A. - American Depositary Shares (NQ:IPHA)

1.500 UNCHANGED
Delayed Quote Updated: 3:58 PM EDT, Oct 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 11,621
Open 1.490
Bid (Size) 1.480 (300)
Ask (Size) 1.510 (300)
Prev. Close 1.500
Today's Range 1.475 - 1.520
52wk Range 1.170 - 2.710
Shares Outstanding 78,986,490
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Innate Pharma to Participate in the Stifel Healthcare Conference and Jefferies Global Healthcare Conference
October 21, 2026
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Announces Conference Call for Third Quarter 2026 Business and Financial Update
October 20, 2026
From Innate Pharma SA
Via Business Wire

Performance

52-Week Range 44.6% below 52-week high
1.500
1.1752W Low 2.7152W High
1 Week 6.2% below 1-week high
1.411W Low 1.601W High

Innate Pharma S.A. - American Depositary Shares (IPHA) traded between $1.17 and $2.71 over the past 52 weeks and last traded at $1.50, 44.6% below its 52-week high. Over the past week it ranged between $1.41 and $1.60.

Past 12 Months
+4.9%
-16.7%
-14.8%
+9.5%
-17.6%
-28.2%
1W +$0.07
1M -$0.30
3M -$0.26
6M +$0.13
YTD -$0.32
1Y -$0.59

IPHA was -28.2% over the past year, +9.5% over six months, -17.6% year to date, +4.9% in the last week.

12 Months vs Market
IPHA
-28.2%
DIA
+11.9%
SPY
+13.8%
QQQ
+16.3%
IWM
+13.3%

Over the past 12 months IPHA returned -28.2% versus DIA (Dow) +11.9%, SPY (S&P 500) +13.8%, QQQ (Nasdaq 100) +16.3% and IWM (Russell 2000) +13.3%.

Volume & Liquidity 0.07× 3-mo avg
Today 11,621 3-mo avg 156.6K
1W
16.2K
1M
37.2K
3M
156.6K
6M
113.0K
YTD
79.3K
1Y
112.4K

IPHA most recently traded 11,621 shares against a 3-month average daily volume of 156.6K.

More News

Read More
News headline image
Innate Pharma (IPHA) Q2 2026 Earnings Call Transcript ↗
September 17, 2026
Via The Motley Fool
Topics Earnings
News headline image
Innate Pharma Q2 Earnings Call Highlights ↗
September 17, 2026
Via MarketBeat
Topics Earnings
News headline image
Innate Pharma Reports First Half 2026 Business Update and Financial Results
September 17, 2026
From Innate Pharma SA
Via Business Wire
News headline image
Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions
September 16, 2026
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma to Host Conference Call and Webcast on September 17 for First Half 2026 Financial Results and Business Update
September 10, 2026
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
September 02, 2026
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Secures €30M, Extends Cash Runway Into 2028 ↗
August 14, 2026
Via MarketBeat
News headline image
Innate Pharma Announces Conference Call and Webcast
August 14, 2026
From Innate Pharma SA
Via Business Wire
Unusual volume stocks are being observed in Wednesday's session. ↗
August 12, 2026
Via Chartmill
The trading volume of these stocks is deviating from the norm in today's session. ↗
August 11, 2026
Via Chartmill
News headline image
Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer
August 10, 2026
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma
August 10, 2026
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference
July 23, 2026
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC)
July 21, 2026
From Innate Pharma SA
Via Business Wire
News headline image
Outcome of Innate Pharma’s 2026 Annual General Meeting
May 22, 2026
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma to participate in the Jefferies Global Healthcare Conference
May 19, 2026
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Q1 Earnings Call Highlights ↗
May 13, 2026
Via MarketBeat
Topics Earnings
News headline image
Innate Pharma Reports First Quarter 2026 Business Update and Financial Results
May 13, 2026
From Innate Pharma SA
Via Business Wire
News headline image
Number of Shares and Voting Rights of Innate Pharma as of April 16, 2026
May 12, 2026
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Announces Conference Call and Webcast for Q1 2026 Business Update
May 06, 2026
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma to Participate in the D. Boral Capital Global Conference
April 23, 2026
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026
April 17, 2026
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 21, 2026
April 13, 2026
From Innate Pharma SA
Via Business Wire

Frequently Asked Questions

Is Innate Pharma S.A. - American Depositary Shares publicly traded?
Yes, Innate Pharma S.A. - American Depositary Shares is publicly traded.
What exchange does Innate Pharma S.A. - American Depositary Shares trade on?
Innate Pharma S.A. - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Innate Pharma S.A. - American Depositary Shares?
The ticker symbol for Innate Pharma S.A. - American Depositary Shares is IPHA on the Nasdaq Stock Market
What is the current price of Innate Pharma S.A. - American Depositary Shares?
The current price of Innate Pharma S.A. - American Depositary Shares is 1.500
When was Innate Pharma S.A. - American Depositary Shares last traded?
The last trade of Innate Pharma S.A. - American Depositary Shares was at 10/23/26 03:58 PM ET
What is the market capitalization of Innate Pharma S.A. - American Depositary Shares?
The market capitalization of Innate Pharma S.A. - American Depositary Shares is 118.48M
How many shares of Innate Pharma S.A. - American Depositary Shares are outstanding?
Innate Pharma S.A. - American Depositary Shares has 118M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap